Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was and whether it warranted making the drug available for patients facing a fatal disease with few other options.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by analysts at HC Wainwright in ...
Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...
Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, ...
Investor's Business Daily on MSN2d
Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.Dystrophin helps keep muscles intact and functional.William Blair's Corwin noted two patients died following treatment with Novartis' Zolgensma, a treatment for spinal muscular atrophy."Overall, we ...
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...
2don MSN
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback